Nektar Therapeutics (Nasdaq: NKTR) reported positive results from the SUMMIT-07 Phase 3 efficacy study of NKTR-181 sending the stock price soaring $6.61 to close at $22.11.
Nektar Therapeutics reports upbeat study results
March 20, 2017 at 17:10 PM EDT
